ReviewImmunotherapy2026
Advances in immunotherapy for cytomegalovirus infection following allogeneic hematopoietic stem cell transplantation.
Review in Immunotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective curative therapy for hematologic malignancies. However, post-transplant cytomegalovirus (CMV) infection remains a common and serious complication, significantly impacting patient prognosis and survival. Currently available antiviral agents are limited by bone marrow suppression, nephrotoxicity, drug resistance, and high cost, highlighting the need for alternative therapeutic strategies. Advances in immunotherapy - including CMV-specific T cells (CMV-CTL), TCR-engineered T cells (CMV-TCR-T), and natural killer (NK) cell therapies - as well as antibody-based approaches and prophylactic vaccines, provide new avenues for CMV management. Future treatment paradigms may integrate antiviral therapy, immunotherapy, and vaccination to improve outcomes in patients experiencing CMV reactivation after transplantation. This review summarizes the current progress of immunotherapeutic strategies for CMV infection following allo-HSCT. Relevant literature was identified through PubMed, Embase, and Web of Science databases, covering the period from January 2000 to December 2025.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.